NXL Key Statistics, Chart & Performance
The current stock price of NXL is 0.5699 USD. In the past month the price decreased by -40.83%. In the past year, price decreased by -82.21%.
NXL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.17 | 218.42B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.13 | 201.85B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.45 | 141.90B | ||
| SYK | STRYKER CORP | 26.78 | 134.88B | ||
| BDX | BECTON DICKINSON AND CO | 13.52 | 55.63B | ||
| IDXX | IDEXX LABORATORIES INC | 53.72 | 54.09B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.26 | 49.60B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.94 | 37.50B | ||
| RMD | RESMED INC | 24.43 | 35.31B | ||
| DXCM | DEXCOM INC | 36.08 | 26.17B | ||
| PODD | INSULET CORP | 62.52 | 20.10B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.16 | 17.90B |
Related stock screener links
About NXL
Company Profile
Nexalin Technology, Inc. designs and develops neurostimulation products. The company is headquartered in Houston, Texas and currently employs 6 full-time employees. The company went IPO on 2022-09-16. The firm has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. The company has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
Company Info
NEXALIN TECHNOLOGY INC
1776 Yorktown, Suite 550
Houston TEXAS US
Employees: 6
Phone: 18322600222
NEXALIN TECHNOLOGY INC / NXL FAQ
Can you describe the business of NEXALIN TECHNOLOGY INC?
Nexalin Technology, Inc. designs and develops neurostimulation products. The company is headquartered in Houston, Texas and currently employs 6 full-time employees. The company went IPO on 2022-09-16. The firm has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. The company has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
What is the stock price of NEXALIN TECHNOLOGY INC today?
The current stock price of NXL is 0.5699 USD. The price increased by 5.54% in the last trading session.
Does NEXALIN TECHNOLOGY INC pay dividends?
NXL does not pay a dividend.
What is the ChartMill technical and fundamental rating of NXL stock?
NXL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for NEXALIN TECHNOLOGY INC?
NEXALIN TECHNOLOGY INC (NXL) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
How many employees does NEXALIN TECHNOLOGY INC have?
NEXALIN TECHNOLOGY INC (NXL) currently has 6 employees.
What is NEXALIN TECHNOLOGY INC worth?
NEXALIN TECHNOLOGY INC (NXL) has a market capitalization of 10.63M USD. This makes NXL a Nano Cap stock.
NXL Technical Analysis
NXL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NXL. No worries on liquidiy or solvency for NXL as it has an excellent financial health rating, but there are worries on the profitability.
NXL Financial Highlights
Over the last trailing twelve months NXL reported a non-GAAP Earnings per Share(EPS) of -0.66. The EPS increased by 0.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -169.31% | ||
| ROE | -182.01% | ||
| Debt/Equity | 0 |
NXL Forecast & Estimates
5 analysts have analysed NXL and the average price target is 4.08 USD. This implies a price increase of 615.92% is expected in the next year compared to the current price of 0.5699.
For the next year, analysts expect an EPS growth of 19.67% and a revenue growth 34.3% for NXL